Filter Results:
(925)
Show Results For
- All HBS Web
(1,282)
- People (5)
- News (172)
- Research (925)
- Events (6)
- Multimedia (12)
- Faculty Publications (759)
Show Results For
- All HBS Web
(1,282)
- People (5)
- News (172)
- Research (925)
- Events (6)
- Multimedia (12)
- Faculty Publications (759)
Sort by
- Research Summary
Marketing and Competition in Pharmaceutical Markets
In his research on pharmaceutical markets, Professor King explores how marketing and product differentiation affect competition among firms in the prescription market for anti-ulcer drugs. Four main results emerge from an analysis of antiulcer drug sales from 1977 to... View Details
- 11 Oct 2011
- Working Paper Summaries
US Healthcare Reform and the Pharmaceutical Industry
- August 2007
- Teaching Note
Teva Pharmaceutical Industries, Ltd (TN)
By: Tarun Khanna and Krishna G. Palepu
Teaching note to 707441. View Details
- September 1988
- Background Note
Note on the Pharmaceutical Industry
Keywords: Pharmaceutical Industry
Herzlinger, Regina E. "Note on the Pharmaceutical Industry." Harvard Business School Background Note 189-076, September 1988.
- April 1990
- Case
International Pharmaceuticals Inc. (Abridged)
By: James E. Austin
Keywords: Pharmaceutical Industry
Austin, James E. "International Pharmaceuticals Inc. (Abridged)." Harvard Business School Case 290-015, April 1990.
- July 2002 (Revised December 2002)
- Case
Phase Two: The Pharmaceutical Industry Responds to AIDS
By: Debora L. Spar
Describes how major pharmaceutical firms changed their strategy and pricing policies in the years 2000 to 2002 to respond to the growing AIDS epidemic in Africa. View Details
Keywords: International Finance; Health Pandemics; Corporate Social Responsibility and Impact; Pharmaceutical Industry; Africa
Spar, Debora L., and Nick Bartlett. "Phase Two: The Pharmaceutical Industry Responds to AIDS." Harvard Business School Case 703-005, July 2002. (Revised December 2002.)
- February 1998 (Revised May 1998)
- Case
Merck-Medco: Vertical Integration in the Pharmaceutical Industry
By: V. Kasturi Rangan and Marie Bell
Records the analyses and actions taken by Merck Pharmaceuticals in its acquisition of Medco, a channel intermediary (called "pharmacy benefit manager"). While many of its competitors seem to be faring poorly, Merck seems to have managed the Medco integration superbly. View Details
Keywords: Vertical Integration; Organizational Change and Adaptation; Competitive Strategy; Marketing Channels; Mergers and Acquisitions; Pharmaceutical Industry
Rangan, V. Kasturi, and Marie Bell. "Merck-Medco: Vertical Integration in the Pharmaceutical Industry." Harvard Business School Case 598-091, February 1998. (Revised May 1998.)
- September 2021 (Revised October 2022)
- Supplement
Hester Pharmaceuticals (B): Securing Supply
By: Dante Roscini and John Masko
Supplements the (A) case. In late 2020, demand for Hester Pharmaceutical’s (Hester’s) breakthrough oncology drug Akrozumab was outstripping the company’s most optimistic projections. In order to increase manufacturing capacity and meet the demand, Hester was... View Details
Keywords: COVID-19 Pandemic; Cost vs Benefits; Trade; Supply Chain; Global Strategy; Buildings and Facilities; Operations; Health Care and Treatment; Demand and Consumers; Global Range; Globalized Markets and Industries; Pharmaceutical Industry; Italy; China; United States; Germany
Roscini, Dante, and John Masko. "Hester Pharmaceuticals (B): Securing Supply." Harvard Business School Supplement 722-009, September 2021. (Revised October 2022.)
- January 1990 (Revised January 1993)
- Teaching Note
International Pharmaceuticals Inc., Teaching Note
By: W. Carl Kester
Keywords: Pharmaceutical Industry
- February 2003 (Revised April 2004)
- Case
Pharmaceutical Industry, The: Challenges in the New Century
By: Stephen P. Bradley and James Weber
Provides a broad overview of the numerous internal and external forces that were driving change in the global pharmaceutical industry in 2003. These forces--including downward price pressures, political and social pressures, increased development costs, new... View Details
Keywords: Business Model; Change; Cost; Price; Globalization; Government and Politics; Brands and Branding; Industry Growth; Society; Competition; Consolidation; Technology; Pharmaceutical Industry
Bradley, Stephen P., and James Weber. "Pharmaceutical Industry, The: Challenges in the New Century." Harvard Business School Case 703-489, February 2003. (Revised April 2004.)
- August 1994
- Teaching Note
Yamanouchi Pharmaceutical Co., Ltd. TN
By: Robin Cooper and Robert S. Kaplan
Keywords: Pharmaceutical Industry
- February 2002 (Revised March 2002)
- Case
India's Intellectual Property Rights Regime and the Pharmaceutical Industry
In 1970, the Indian government significantly revised its patent law, Patents and Design Act of 1911. The 1911 act was enacted when India was a colony of Great Britain, and it was controversial because it led to the total dominance of India's pharmaceutical market by... View Details
Huang, Yasheng, and Hal Hogan. "India's Intellectual Property Rights Regime and the Pharmaceutical Industry." Harvard Business School Case 702-039, February 2002. (Revised March 2002.)
- October 1992 (Revised April 1993)
- Supplement
ImmuLogic Pharmaceutical Corporation (B4): Phillip Gross
By: Josh Lerner
Supplements the (A) case. View Details
Keywords: Pharmaceutical Industry
Lerner, Josh. "ImmuLogic Pharmaceutical Corporation (B4): Phillip Gross." Harvard Business School Supplement 293-070, October 1992. (Revised April 1993.)
- June 1990
- Teaching Note
International Pharmaceuticals Inc. (Abridged), Teaching Note
By: James E. Austin and Tomas Otto Kohn
Keywords: Pharmaceutical Industry
- 1995
- Chapter
Pharmaceutical Companies and Health Care Reform
By: Arthur A. Daemmrich
- March 1993 (Revised May 1998)
- Teaching Note
ImmuLogic Pharmaceutical Corporation (Series) TN
By: Josh Lerner
Teaching Note for (9-293-066--071) and (9-293-087). View Details
Keywords: Pharmaceutical Industry
- January 2006 (Revised May 2007)
- Supplement
Endo Pharmaceuticals (D): Hatch-Waxman Change
By: Richard G. Hamermesh and Brian DeLacey
Hamermesh, Richard G., and Brian DeLacey. "Endo Pharmaceuticals (D): Hatch-Waxman Change." Harvard Business School Supplement 806-067, January 2006. (Revised May 2007.)
- January 2006 (Revised May 2007)
- Supplement
Endo Pharmaceuticals (B): Merger Decision
By: Richard G. Hamermesh and Brian DeLacey
Hamermesh, Richard G., and Brian DeLacey. "Endo Pharmaceuticals (B): Merger Decision." Harvard Business School Supplement 806-065, January 2006. (Revised May 2007.)
- October 1992 (Revised March 1993)
- Supplement
ImmuLogic Pharmaceutical Corporation (B1): Malcolm Gefter
By: Josh Lerner
Supplements the (A) case. View Details
Keywords: Pharmaceutical Industry
Lerner, Josh. "ImmuLogic Pharmaceutical Corporation (B1): Malcolm Gefter." Harvard Business School Supplement 293-067, October 1992. (Revised March 1993.)